Federal Register / Vol. 89, No. 26 / Wednesday, February 7, 2024 / Notices 8433 

laboratories in Rwanda, and establishes 

relations and collaborations with other 

national and international agencies 

carrying out similar responsibilities. No 

other agency in the public or private 

sector performs this responsibility. 

South African Medical Research 

Council is in a unique position to 

conduct this work, as it is a government 

body responsible for biomedical 

research of national importance and is 

the only agency with this direct 

governmental mandate in South Africa. 

SANAC is in a unique position to 

conduct this work, as it is mandated to 

coordinate a truly multi-sectoral 

response to the epidemics at a national 

and sub-national level. Therefore, 

SANAC is authorized to collaborate 

with government departments, the 

private health sector, other development 

partners, and non-governmental 

organizations (NGOS) to develop 

strategies to reach epidemic control. 

TACAIDS is in a unique position to 

conduct this work, as it has sole legal 

authority to provide strategic multisectorial leadership and to coordinate 

and strengthen efforts of all stakeholders 

involved in the national HIV/AIDS 

response. TACAIDS has 16 functions to 

aid in achieving their mandate. 

PO–RALG is in a unique position to 

conduct this work, as it is legally the 

only government agency that interprets 

national policies, strategies, and 

guidelines related to health and social 

welfare sector development, financing, 

and human resources; provides 

supportive supervision and mentorship 

to RAs and LGAs; and ensures 

implementation of policies and 

regulations by RAs and LGAs. PO– 

RALG has oversight and management of 

all dispensaries, health facilities, and 

regional hospitals, as well as all health 

care workers. 

VAAC is in a unique position to 

conduct this work, as it uniquely 

qualified for this funding opportunity 

because of their political mandate, 

clearly acknowledged leadership by all 

partners, and significant experience to 

continue a strong and vital coordinating 

role for HIV programs. 

Summary of the award: 

Recipient: Namibia Ministry of Health 

and Social Services (MOHSS), Rwanda 

Biomedical Center, South African 

Medical Research Council, South 

African National AIDS Council Trust 

(SANAC), Tanzania Commission for 

AIDS (TACAIDS), President’s Office— 

Regional Administration and Local 

Government (PO–RALG), and Vietnam 

Administration for HIV/AIDS Control 

(VAAC). 

Purpose of the Award: The purpose of 

these awards is to strengthen 

comprehensive and integrated service 

delivery for prevention and implement 

strategies and activities that strengthen 

local entities, support the coordination, 

management, and monitoring of multisectoral implementation, foster the 

government’s capacity to provide 

comprehensive management of the HIV 

program, and implement a sustainable 

and quality-assured HIV diagnostic, 

testing, and health information 

management program in Namibia, 

Rwanda, South Africa, Tanzania, and 

Vietnam. 

Amount of Award: For MOHSS, the 

approximate year 1 funding amount will 

be $8,000,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. Funding amounts 

for years 2–5 will be set at continuation. 

Amount of Award: For Rwanda 

Biomedical Center, the approximate 

year 1 funding amount will be 

$4,000,000 in Federal Fiscal Year (FYY) 

2024 funds, subject to the availability of 

funds. Funding amounts for years 2–5 

will be set at continuation. 

Amount of Award: For South African 

Medical Research Council, the 

approximate year 1 funding amount will 

be $(3,000,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. Funding amounts 

for years 2–5 will be set at continuation. 

Amount of Award: For SANAC, the 

approximate year 1 funding amount will 

be $3,000,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. Funding amounts 

for years 2–5 will be set at continuation. 

Amount of Award: For TACAIDS, the 

approximate year 1 funding amount will 

be $500,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. Funding amounts 

for years 2–5 will be set at continuation. 

Amount of Award: For PO–RALG, the 

approximate year 1 funding amount will 

be $500,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. 

Amount of Award: For VAAC, the 

approximate year 1 funding amount will 

be $6,000,000 in Federal Fiscal Year 

(FYY) 2024 funds, subject to the 

availability of funds. Funding amounts 

for years 2–5 will be set at continuation. 

Authority: These programs are 

authorized under Public Law 108–25 

(the United States Leadership Against 

HIV AIDS, Tuberculosis and Malaria 

Act of 2003) [22 U.S.C. 7601, et seq.] 

and Public Law 110–293 (the Tom 

Lantos and Henry J. Hyde United States 

Global Leadership Against HIV/AIDS, 

Tuberculosis, and Malaria 

Reauthorization Act of 2008), and 

Public Law 113–56 (PEPFAR 

Stewardship and Oversight Act of 2013). 

Period of Performance: The period for 

these awards will be September 30, 

2024, through September 29, 2029. 

Dated: January 24, 2024. 

Jamie Legier, 

Acting Director, Office of Grants Services, 

Acting Chief Grants Management Officer, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–02505 Filed 2–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Sole Source 

Cooperative Agreement To Fund the 

Pan-American Health Organization 

(PAHO) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $8,000,000, 

with an expected total funding of 

approximately $50,000,000 over a 5-year 

period, to the Pan-American Health 

Organization (PAHO). The award will 

support strengthening immunization 

systems; ensuring polio free certification 

status; maintaining measles, rubella, 

and neonatal tetanus elimination; and 

prevention of other vaccine-preventable 

diseases (VPDs) in the Americas region. 

This award builds upon and continues 

work previously supported by PAHO 

through a cooperative agreement under 

CDC–RFA–GH–1901, ‘‘Cooperative 

Agreement with the Pan American 

Health Organization: Protecting and 

Strengthening Immunization Programs 

in the Americas.’’ 

DATES: The period for this award will be 

May 1, 2024, through April 30, 2029. 

FOR FURTHER INFORMATION CONTACT: 

Mary A. Mulholland, (Global Health 

Center, Centers for Disease Control and 

Prevention, 1600 Clifton Rd. NE, 

Atlanta, GA 30333, Telephone: 404– 

553–7371, Email: mmulholland@

cdc.gov. 

SUPPLEMENTARY INFORMATION: The sole 

source award will establish a 

cooperative agreement that will build 

upon the achievements of past 

cooperative agreements with PAHO, 

while forging new collaborations to 

strengthen the Expanded Program on 

Immunization in the Americas as a 


khammond on DSKJM1Z7X2PROD with NOTICES
8434 Federal Register / Vol. 89, No. 26 / Wednesday, February 7, 2024 / Notices 

whole. Supported activities will 

includes development of standards for 

national immunization programs, 

development of national immunization 

program capacity to prevent, detect and 

respond to VPDs, and maintain the 

status of polio eradication; rubella, 

measles, and neonatal tetanus 

elimination; and support the 

elimination of Hepatitis B. To achieve 

these strategies, the recipient will 

provide direct technical cooperation to 

Member States through both its regional 

headquarters and country offices. 

PAHO is in a unique position to 

conduct this work, as it functions as the 

lead specialized health agency within 

the inter-American system and operates 

as the regional office for the Americas 

on behalf of the World Health 

Organization (WHO), the UN’s 

specialized health agency, with 

headquarters in Washington DC. 

Through their presence in the 35 

member countries in the region, PAHO 

promotes technical cooperation between 

countries and works in partnership with 

ministries of health and other 

government agencies, civil society 

organizations, other international 

agencies, universities, social security 

agencies, community groups, and other 

partners. During nearly three decades of 

partnership with CDC’s Global 

Immunization Division, PAHO has 

made outstanding progress towards 

strengthening routine immunization and 

surveillance systems for polio, measles, 

rubella, and congenital rubella 

syndrome; including maintaining the 

revolving fund for the bulk purchase of 

vaccines for member countries; 

developing a strong platform for 

strengthening surveillance of other 

VPDs; and maintaining its polio-free 

certification since 1994, as well as 

verification of regional rubella and CRS 

elimination since 2015 and regional 

measles elimination since 2016. 

Summary of the award: 

Recipient: Pan-American Health 

Organization (PAHO). 

Purpose of the Award: The purpose of 

this award is to support strengthening 

immunization systems; ensuring polio 

free certification status; maintaining 

measles, rubella, and neonatal tetanus 

elimination; and prevention of other 

VPDs in the Americas region, in 

alignment with the US Government 

endorsed Global Polio Eradication 

Initiative, the Immunization Agenda 

2030 and CDC’s Global Immunization 

Strategic Framework 2021–2030. 

Additionally, this NOFO supports 

CDC’s Global Health Strategy which 

focuses on protecting and improving the 

health, safety, security, and well-being 

of Americans by reducing morbidity and 

mortality worldwide; improving 

capabilities to prepare for and respond 

to infectious diseases and other 

emerging health threats and public 

health emergencies; and maximizing 

potential of CDC’s global programs to 

achieve public health impact. 

Amount of Award: $8,000,000 in 

Federal fiscal year (FFY) 2024 funds, 

with a total estimated $ 50,000,000 for 

the 5-year period of performance, 

subject to availability of funds. Funding 

amounts for years 2–5 will be set at 

continuation. 

Authority: This program is authorized 

under Section 307 of the PHS Act (42 

U.S.C 242); section 317(k)(1) and (2) of 

the PHS Act (42 U.S.C. 247b(k)(1) and 

(2). 

Period of Performance: May 1, 2024, 

through April 30, 2029. 

Dated: January 24, 2024. 

Jamie Legier, 

Acting Director, Office of Grants Services, 

Acting Chief Grants Management Officer, 

Centers for Disease Control and Prevention. 

[FR Doc. 2024–02507 Filed 2–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[Document Identifier: CMS–10448] 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

AGENCY: Centers for Medicare & 

Medicaid Services, Health and Human 

Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Medicare & 

Medicaid Services (CMS) is announcing 

an opportunity for the public to 

comment on CMS’ intention to collect 

information from the public. Under the 

Paperwork Reduction Act of 1995 

(PRA), federal agencies are required to 

publish notice in the Federal Register 

concerning each proposed collection of 

information, including each proposed 

extension or reinstatement of an existing 

collection of information, and to allow 

a second opportunity for public 

comment on the notice. Interested 

persons are invited to send comments 

regarding the burden estimate or any 

other aspect of this collection of 

information, including the necessity and 

utility of the proposed information 

collection for the proper performance of 

the agency’s functions, the accuracy of 

the estimated burden, ways to enhance 

the quality, utility, and clarity of the 

information to be collected, and the use 

of automated collection techniques or 

other forms of information technology to 

minimize the information collection 

burden. 

DATES: Comments on the collection(s) of 

information must be received by the 

OMB desk officer by March 8, 2024. 

ADDRESSES: Written comments and 

recommendations for the proposed 

information collection should be sent 

within 30 days of publication of this 

notice to www.reginfo.gov/public/do/ 

PRAMain. Find this particular 

information collection by selecting 

‘‘Currently under 30-day Review—Open 

for Public Comments’’ or by using the 

search function. 

To obtain copies of a supporting 

statement and any related forms for the 

proposed collection(s) summarized in 

this notice, please access the CMS PRA 

website by copying and pasting the 

following web address into your web 

browser: https://www.cms.gov/ 

Regulations-and-Guidance/Legislation/

PaperworkReductionActof1995/PRAListing. 

FOR FURTHER INFORMATION CONTACT: 

William Parham at (410) 786–4669. 

SUPPLEMENTARY INFORMATION: Under the 

Paperwork Reduction Act of 1995 (PRA) 

(44 U.S.C. 3501–3520), federal agencies 

must obtain approval from the Office of 

Management and Budget (OMB) for each 

collection of information they conduct 

or sponsor. The term ‘‘collection of 

information’’ is defined in 44 U.S.C. 

3502(3) and 5 CFR 1320.3(c) and 

includes agency requests or 

requirements that members of the public 

submit reports, keep records, or provide 

information to a third party. Section 

3506(c)(2)(A) of the PRA (44 U.S.C. 

3506(c)(2)(A)) requires federal agencies 

to publish a 30-day notice in the 

Federal Register concerning each 

proposed collection of information, 

including each proposed extension or 

reinstatement of an existing collection 

of information, before submitting the 

collection to OMB for approval. To 

comply with this requirement, CMS is 

publishing this notice that summarizes 

the following proposed collection(s) of 

information for public comment: 

1. Type of Information Collection 

Request: Revision of a currently 

approved collection; Title of 

Information Collection: Essential Health 

Benefits Benchmark Plans; Use: On 

March 23, 2010, the Patient Protection 

and Affordable Care Act (PPACA; Pub. 

L. 111–148) was signed into law, and on 

March 30, 2010, the Health Care and 

Education Reconciliation Act of 2010 

(Pub. L. 111–152) was signed into law. 


khammond on DSKJM1Z7X2PROD with NOTICES